Shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) have received a consensus recommendation of "Buy" from the seven research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $38.67.
A number of equities research analysts have commented on the company. JMP Securities reiterated a "market outperform" rating and issued a $33.00 price target on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. Citizens Jmp upgraded ABIVAX Société Anonyme to a "strong-buy" rating in a research report on Wednesday, December 4th.
Read Our Latest Report on ABVX
Institutional Trading of ABIVAX Société Anonyme
A number of institutional investors and hedge funds have recently modified their holdings of the business. abrdn plc boosted its holdings in shares of ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company's stock worth $3,645,000 after acquiring an additional 198,225 shares during the period. Point72 Asset Management L.P. increased its position in shares of ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company's stock valued at $6,254,000 after purchasing an additional 119,300 shares during the last quarter. Walleye Capital LLC lifted its holdings in shares of ABIVAX Société Anonyme by 45.8% in the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock worth $2,965,000 after acquiring an additional 80,807 shares during the last quarter. BNP Paribas Financial Markets boosted its position in ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock valued at $150,000 after buying an additional 5,900 shares during the period. Finally, R Squared Ltd bought a new position in shares of ABIVAX Société Anonyme during the fourth quarter valued at about $36,000. 47.91% of the stock is owned by hedge funds and other institutional investors.
ABIVAX Société Anonyme Price Performance
ABVX traded down $0.08 on Thursday, reaching $6.16. The stock had a trading volume of 112,325 shares, compared to its average volume of 128,979. ABIVAX Société Anonyme has a fifty-two week low of $5.54 and a fifty-two week high of $17.02. The firm has a 50-day moving average of $7.72 and a 200-day moving average of $10.05.
About ABIVAX Société Anonyme
(
Get Free ReportABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Featured Stories
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
